touchLearning Activities
The COVID-19 pandemic accelerated the development of mRNA technologies, most notably with the creation of mRNA vaccines targeting SARS-CoV-2. While these vaccines helped control the pandemic, their potential may extend beyond infectious diseases, with growing interest in their potential application ...
We’re thrilled to welcome Dr. Ken Kato (National Cancer Center Hospital, Tokyo, Japan) to discuss the unique advantages and challenges of conducting cancer research in Japan. Key advantages include robust regulatory support, streamlined trial approvals and strong collaboration with ...
Liver cancer remains a significant global health challenge, often going undetected until it has progressed to advanced stages. A major barrier to early detection is the lack of awareness about liver health and risk factors, such as chronic liver diseases ...
touchONCOLOGY are delighted to support Global Liver Institute (GLI) as they officially launch their seventh annual #OctoberIs4Livers campaign, aiming to raise awareness about liver cancer and the disparities that affect communities at risk. This initiative comes in observance of Liver Cancer Awareness Month and this year focuses on the important theme “Addressing Disparities in Liver Cancer Care.”
A recent study examining prostate cancer trends across 26 European countries has provided vital data for the ongoing discussions around implementing EU-wide screening programs.
We’re looking forward to the ESMO Congress 2024 which is taking place in Madrid between 13- 17 September, 2024. Promising attendees an opportunity to explore the latest technologies, treatments, and products in the field of oncology, we are excited to provide independent, ...
In our latest episode, we delve into the world of space medicine to explore how drug crystallization in microgravity could revolutionize biologic drug administration. Joining us is Dr Katie King, CEO of BioOrbit, to discuss the science, challenges, and technological advancements that could make space-based drug production a reality.
At this year’s European Society for Blood and Marrow Transplantation (EBMT) meeting in Glasgow, Scotland, graft-versus-host disease (GVHD) emerged as a central topic of discussion. The conference featured a wealth of innovative research, with numerous abstracts presenting advances in the management of chronic and refractory GVHD, offering new hope for patients facing this challenging complication. Here we explore some of the most exciting abstracts presented.
A new study published in the Journal of Radiology reveals promising advancements in the use of artificial intelligence (AI) to improve radiology reporting, particularly in the context of prostate cancer detection. The research demonstrates that AI can significantly enhance the accuracy and efficiency of radiological assessments, especially in complex cases involving large sets of imaging data.
Colorectal cancer is the third most common cancer worldwide and is the second leading cause of cancer-related deaths for men and women combined. The disease is on the rise in younger generations. It is the leading cause of cancer-related deaths in men under 50, and researchers predict it will become the leading cause in men and women ages 20-49 within the next decade. However, it remains less known and less funded than other cancers. For comparison, breast cancer, which has benefited greatly from major funding that contributed to significant research advancements, has a five-year survival rate of 30%, whereas the five-year survival rate for colorectal cancer is drastically lower at only 13%. To achieve better outcomes, the Colorectal Cancer Alliance (Alliance) is reinvigorating its mission to end colorectal cancer with the launch of Project Cure CRC.
The ESMO GI 2024 meeting, held this year in Munich, Germany, brought together researchers and clinicians from around the world to discuss recent developments in gastrointestinal malignancies.
In line with the continuously expanding molecular landscape of cancer, the ESMO Precision Medicine Working Group (PMWG) has revised its recommendations for tumour next-generation sequencing (NGS).
Few alliances have impacted patient care as significantly as the Myeloproliferative Neoplasms Research Consortium (MPN-RC). Established in 2006, the MPN-RC is an international group dedicated to advancing research and developing innovative treatment strategies for myeloproliferative neoplasms. In this episode, we speak with Prof. John Mascarenhas, about the coalition's founding, operational mechanics and how their efforts have led to paradigm-shifting therapies in the field.
The annual ASCO2024 meeting was packed as always with the latest trial data and treatment advances in oncology.
Highlights from ESGO 2024, featuring the latest data and insights presented at the meeting.
touchONCOLOGY
Register Now!
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
- Save your progress for video
- Keep track of your CME credits
- Add personalised learning notes
- Receive updates from course leaders and faculty
- Be the first to hear about new and exciting interactive learning opportunities
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
